Bio-Techne’s 2026 Growth Outlook and Industry Positioning
Bio-Techne anticipates strong growth prospects in its Spatial Biology and Proteomics platforms through 2026, driven by innovation and market expansion.
Read postDetailed company information
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q3Released: May 06, 2026
Earnings Transcript for 2026 - Q2Released: Feb 04, 2026
Earnings Transcript for 2026 - Q1Released: Nov 05, 2025
Earnings Transcript for 2025 - Q4Released: Aug 06, 2025
Earnings Transcript for 2025 - Q3Released: May 07, 2025
Earnings Transcript for 2025 - Q2Released: Feb 05, 2025
Earnings Transcript for 2025 - Q1Released: Oct 30, 2024
Earnings Transcript for 2024 - Q4Released: Aug 07, 2024
Earnings Transcript for 2024 - Q3Released: May 01, 2024
Earnings Transcript for 2024 - Q2Released: Feb 01, 2024
Earnings Transcript for 2024 - Q1Released: Oct 31, 2023
Earnings Transcript for 2023 - Q4Released: Aug 08, 2023
Earnings Transcript for 2023 - Q3Released: May 03, 2023
Earnings Transcript for 2023 - Q2Released: Feb 02, 2023
Earnings Transcript for 2023 - Q1Released: Nov 01, 2022
Earnings Transcript for 2022 - Q4Released: Aug 06, 2022
Earnings Transcript for 2022 - Q3Released: May 04, 2022
Earnings Transcript for 2022 - Q2Released: Feb 01, 2022
Earnings Transcript for 2022 - Q1Released: Nov 02, 2021
Earnings Transcript for 2021 - Q4Released: Aug 07, 2021
Earnings Transcript for 2021 - Q3Released: May 09, 2021
Earnings Transcript for 2021 - Q2Released: Feb 02, 2021
Earnings Transcript for 2021 - Q1Released: Nov 08, 2020
Earnings Transcript for 2020 - Q4Released: Aug 04, 2020
Bio-Techne anticipates strong growth prospects in its Spatial Biology and Proteomics platforms through 2026, driven by innovation and market expansion.
Read postBio-Techne's spatial biology and proteomics platforms are poised for significant growth into 2026, driven by content-rich data demand and strategic platform differentiation.
Read post